J A Maroun

Summary

Affiliation: University of Ottawa
Country: Canada

Publications

  1. ncbi request reprint A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer
    J A Maroun
    Medical Oncology, The Ottawa Hospital Regional Cancer Centre, 501 Smyth Road, Ottawa, Ont, Canada K1H 8L6
    Eur J Cancer 42:193-9. 2006
  2. ncbi request reprint Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
    J A Maroun
    The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
    Ann Oncol 17:1371-8. 2006
  3. pmc Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
    D J Jonker
    Ottawa Regional Cancer Centre, London, Ontario, Canada
    Br J Cancer 82:1789-94. 2000
  4. ncbi request reprint Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens
    A S Haqqani
    Department of Biochemistry, Microbiology and Immunology, Ottawa, Ontario, Canada
    J Histochem Cytochem 47:1563-74. 1999
  5. ncbi request reprint Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback
    G P Browman
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 16:1226-31. 1998
  6. ncbi request reprint Capecitabine in the management of colorectal cancer
    J A Maroun
    Ottawa Regional Cancer Centre, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada
    Expert Rev Anticancer Ther 1:327-33. 2001
  7. pmc Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Br J Cancer 90:1190-7. 2004

Collaborators

Detail Information

Publications7

  1. ncbi request reprint A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer
    J A Maroun
    Medical Oncology, The Ottawa Hospital Regional Cancer Centre, 501 Smyth Road, Ottawa, Ont, Canada K1H 8L6
    Eur J Cancer 42:193-9. 2006
    ..3%) experienced partial response. Further evaluation in a randomized study compared to sequential doublets is warranted. Triple combinations could be relevant in curative settings for high-risk patients...
  2. ncbi request reprint Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
    J A Maroun
    The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
    Ann Oncol 17:1371-8. 2006
    ..Aplidine is a cyclic depsipeptide isolated from the marine tunicate Aplidium albicans...
  3. pmc Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
    D J Jonker
    Ottawa Regional Cancer Centre, London, Ontario, Canada
    Br J Cancer 82:1789-94. 2000
    ..Chemotherapy significantly prolongs 1-year survival for patients with metastatic colorectal cancer, and should be offered to those with good performance status...
  4. ncbi request reprint Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens
    A S Haqqani
    Department of Biochemistry, Microbiology and Immunology, Ottawa, Ontario, Canada
    J Histochem Cytochem 47:1563-74. 1999
    ..Normal colon mucosa showed weak staining, whereas some colorectal cancer specimens stained very strongly with hTS7.4. A clinical study of colorectal cancer using this antibody is in progress. (J Histochem Cytochem 47:1563-1573, 1999)..
  5. ncbi request reprint Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback
    G P Browman
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 16:1226-31. 1998
    ....
  6. ncbi request reprint Capecitabine in the management of colorectal cancer
    J A Maroun
    Ottawa Regional Cancer Centre, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada
    Expert Rev Anticancer Ther 1:327-33. 2001
    ..The rational development of this targeted drug with its selective activation in tumor tissue is highlighted. The clinical development of capecitabine and its present and future role in the management of colorectal cancer are reviewed...
  7. pmc Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Br J Cancer 90:1190-7. 2004
    ..Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy...